Venetoclax study in relapsed CLL using early tumor tracking
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with CLL or SLL according to standard guidelines
- Your CLL is “active” right now—such as major weight loss, fevers/night sweats without infection, or worsening blood counts or swelling
- You’re 18 or older, and your day-to-day functioning is fairly good (ECOG 0–2)
- You can take venetoclax after a planned ramp-up period and you have a cancer doctor who will manage your care
- You can do required testing and visits, including swallowing the capsules
- Before treatment, you can complete required blood/compatibility testing (including G6PD and HLA tests)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and obinutuzumab) given for a limited time to people whose CLL/SLL has come back after prior treatment. The goal is to see if this combination can control the cancer and possibly allow a treatment-free period.
This trial tests three drugs—roginolisib, venetoclax, and rituximab—for people with CLL that has come back or not responded after at least two prior treatments, including a BTK inhibitor. The goal is to see if this combination is safe and effective.
This trial tests a new combination of three drugs for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment yet. The goal is to see if this approach helps control the disease with fewer side effects.
This trial tests giving venetoclax to people with CLL who are already taking a BTK inhibitor and have stable disease. The goal is to see if adding venetoclax can help eliminate any remaining CLL cells.
This early-phase study tests whether combining venetoclax (a tablet) with epcoritamab (a targeted antibody) can control CLL/SLL that has come back or did not respond. It may help by boosting the immune system’s ability to attack the cancer while keeping the treatment schedule in cycles.
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.